JHVEPhoto
Eli Lilly (NYSE:LLY) made headlines this morning with an announcement that their anti-amyloid antibody donanemab hit its endpoints in a Phase III clinical trial. So this definitely needs a close look! Here’s Lilly’s press release. Ryan
Lilly's New Donanemab Data For Alzheimer's
Summary
- Eli Lilly made headlines with an announcement that their anti-amyloid antibody donanemab hit its endpoints in a Phase III clinical trial.
- The natural comparison is with lecanemab (Leqembi), the recently approved antibody from Eisai and Biogen.
- Lilly’s donanemab trial had a primary endpoint of change in that baseline decline after 18 months on their iADRS, but their antibody is dosed differently.
Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases.
To contact Derek, email him directly: derekb.lowe@gmail.com (mailto:derekb.lowe@gmail.com)